Spicer, James

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Yap, T. A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., Ang, J., Temple, G., Bell, S., Shahidi, M., et al. (2010) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 349

A Multicentre Randomised Phase III Trial Comparing Pembrolizumab versus Single-Agent Chemotherapy for Advanced Pre-Treated Malignant Pleural Mesothelioma: The European Thoracic Oncology Platform (ETOP 9–15) PROMISE-Meso Trial

Popat, S., Curioni-Fontecedro, A., Dafni, U., Shah, R., O'Brien, M., Pope, A., Fisher, P., Spicer, J., Roy, A., Gilligan, D., et al. (2020) · Annals of Oncology

Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies

Cited by 271

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J.-P., Arkenau, H.-T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., et al. (2019) · The Lancet Oncology

Monoclonal and Polyclonal Antibodies ResearchLung Cancer Treatments and Mutations

Cited by 237

IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states

Pellizzari, G., Hoskin, C., Crescioli, S., Mele, S., Gotovina, J., Chiaruttini, G., Bianchini, R., Ilieva, K., Bax, H. J., Papa, S., et al. (2019) · EBioMedicine

Immune cells in cancerMonoclonal and Polyclonal Antibodies Research

Cited by 77

IgE immunotherapy: A novel concept with promise for the treatment of cancer

Josephs, D. H., Spicer, J. F., Karagiannis, P., Gould, H. J., & Karagiannis, S. N. (2014) · mAbs

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 58

Harnessing Therapeutic IgE Antibodies to Re-educate Macrophages against Cancer

Pellizzari, G., Bax, H. J., Josephs, D. H., Gotovina, J., Jensen-Jarolim, E., Spicer, J. F., & Karagiannis, S. N. (2020) · Trends in Molecular Medicine

Immune cells in cancerMonoclonal and Polyclonal Antibodies Research

Cited by 29

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer

Middleton, G., Robbins, H. L., Fletcher, P., Savage, J., Mehmi, M., Summers, Y., Greystoke, A., Steele, N., Popat, S., Jain, P., et al. (2025) · npj Precision Oncology

Lung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer

Cited by 7